Limits...
Oral microencapsulated live Saccharomyces cerevisiae cells for use in renal failure uremia: preparation and in vivo analysis.

Coussa R, Martoni C, Bhathena J, Urbanska AM, Prakash S - J. Biomed. Biotechnol. (2010)

Bottom Line: Orally administrating these microcapsules to uremic rats was found to decrease urea concentrations from 7.29 +/- 0.89 mmol/L to 6.12 +/- 0.90 mmol/L over a treatment period of eight weeks.While creatinine concentrations for both uremic-control and uremic-treatment groups did not differ among each other (P > .05), they were, however, significantly higher than those of the normal control group (P < .05).There were no significant differences in both calcium and phosphate concentrations among all three groups (P > .05).

View Article: PubMed Central - PubMed

Affiliation: Biomedical Technology and Cell Therapy Research Laboratory, Department of Biomedical Engineering, Faculty of Medicine, McGill University, Montréal, QC, Canada H3A 2B4.

ABSTRACT
Orally administrable alginate-poly-L-lysine-alginate (APA) microcapsules containing live yeast cells was investigated for use in renal failure. At all times, yeast cells remain inside the microcapsules, which are then excreted in the stool. During their gastrointestinal passage, small molecules, like urea, diffuse into the yeast microcapsules where they are hydrolyzed. Orally administrating these microcapsules to uremic rats was found to decrease urea concentrations from 7.29 +/- 0.89 mmol/L to 6.12 +/- 0.90 mmol/L over a treatment period of eight weeks. After stopping the treatment, the urea concentrations increased back to uremic levels of 7.64 +/- 0.77 mmol/L. The analysis of creatinine concentrations averaged 39.19 +/- 4.33 micromol/L, 50.83 +/- 5.55 micromol/L, and 50.28 +/- 7.10 micromol/L for the normal-control, uremic-control and uremic-treatment groups, respectively. While creatinine concentrations for both uremic-control and uremic-treatment groups did not differ among each other (P > .05), they were, however, significantly higher than those of the normal control group (P < .05). Uric acid concentrations averaged 80.08 +/- 26.49 micromol/L, 99.92 +/- 26.55 micromol/L, and 86.49 +/- 28.42 micromol/L for the normal-control, uremic-control and uremic-treatment groups, respectively. There were no significant differences in both calcium and phosphate concentrations among all three groups (P > .05). The microbial populations of five tested types of bacteria were not substantially altered by the presence of the yeast APA encapsulated yeast (P > .05).

Show MeSH

Related in: MedlinePlus

Plasma creatinine concentration before, during and after oral administration of APA microencapsulated yeast cells.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2926829&req=5

fig3: Plasma creatinine concentration before, during and after oral administration of APA microencapsulated yeast cells.

Mentions: The analysis of creatinine concentrations averaged 39.19 ± 4.33 μmol/L, 50.83 ± 5.55 μmol/L, and 50.28 ± 7.10 μmol/L for the normal and uremic control as well as the uremic treatment group, respectively (Figure 3). While values for both uremic groups did not differ among each other (P > .05), they were, however, significantly higher than those of the normal control group (P < .05).


Oral microencapsulated live Saccharomyces cerevisiae cells for use in renal failure uremia: preparation and in vivo analysis.

Coussa R, Martoni C, Bhathena J, Urbanska AM, Prakash S - J. Biomed. Biotechnol. (2010)

Plasma creatinine concentration before, during and after oral administration of APA microencapsulated yeast cells.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2926829&req=5

fig3: Plasma creatinine concentration before, during and after oral administration of APA microencapsulated yeast cells.
Mentions: The analysis of creatinine concentrations averaged 39.19 ± 4.33 μmol/L, 50.83 ± 5.55 μmol/L, and 50.28 ± 7.10 μmol/L for the normal and uremic control as well as the uremic treatment group, respectively (Figure 3). While values for both uremic groups did not differ among each other (P > .05), they were, however, significantly higher than those of the normal control group (P < .05).

Bottom Line: Orally administrating these microcapsules to uremic rats was found to decrease urea concentrations from 7.29 +/- 0.89 mmol/L to 6.12 +/- 0.90 mmol/L over a treatment period of eight weeks.While creatinine concentrations for both uremic-control and uremic-treatment groups did not differ among each other (P > .05), they were, however, significantly higher than those of the normal control group (P < .05).There were no significant differences in both calcium and phosphate concentrations among all three groups (P > .05).

View Article: PubMed Central - PubMed

Affiliation: Biomedical Technology and Cell Therapy Research Laboratory, Department of Biomedical Engineering, Faculty of Medicine, McGill University, Montréal, QC, Canada H3A 2B4.

ABSTRACT
Orally administrable alginate-poly-L-lysine-alginate (APA) microcapsules containing live yeast cells was investigated for use in renal failure. At all times, yeast cells remain inside the microcapsules, which are then excreted in the stool. During their gastrointestinal passage, small molecules, like urea, diffuse into the yeast microcapsules where they are hydrolyzed. Orally administrating these microcapsules to uremic rats was found to decrease urea concentrations from 7.29 +/- 0.89 mmol/L to 6.12 +/- 0.90 mmol/L over a treatment period of eight weeks. After stopping the treatment, the urea concentrations increased back to uremic levels of 7.64 +/- 0.77 mmol/L. The analysis of creatinine concentrations averaged 39.19 +/- 4.33 micromol/L, 50.83 +/- 5.55 micromol/L, and 50.28 +/- 7.10 micromol/L for the normal-control, uremic-control and uremic-treatment groups, respectively. While creatinine concentrations for both uremic-control and uremic-treatment groups did not differ among each other (P > .05), they were, however, significantly higher than those of the normal control group (P < .05). Uric acid concentrations averaged 80.08 +/- 26.49 micromol/L, 99.92 +/- 26.55 micromol/L, and 86.49 +/- 28.42 micromol/L for the normal-control, uremic-control and uremic-treatment groups, respectively. There were no significant differences in both calcium and phosphate concentrations among all three groups (P > .05). The microbial populations of five tested types of bacteria were not substantially altered by the presence of the yeast APA encapsulated yeast (P > .05).

Show MeSH
Related in: MedlinePlus